PMS-PIROXICAM SUPPOSITORIES -20MG SUPPOSITORY

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

PIROXICAM

متاح من:

PHARMASCIENCE INC

ATC رمز:

M01AC01

INN (الاسم الدولي):

PIROXICAM

جرعة:

20MG

الشكل الصيدلاني:

SUPPOSITORY

تركيب:

PIROXICAM 20MG

طريقة التعاطي:

RECTAL

الوحدات في الحزمة:

30 SUPPOSITORIES

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

ملخص المنتج:

Active ingredient group (AIG) number: 0114612001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2016-10-28

خصائص المنتج

PRODUCT MONOGRAPH
Pr
pms-PIROXICAM
Piroxicam, USP
10 mg and 20 mg Capsules
10 mg and 20 mg Suppositories
Nonsteroidal Anti-Inflammatory Drug (NSAID)
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue
February 17, 2010
Montreal, Quebec
H4P 2T4
CONTROL # 131400
_ _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................5
ADVERSE
REACTIONS..................................................................................................14
DRUG INTERACTIONS
.................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................22
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL
PHARMACOLOGY.............................................................23
STORAGE AND
STABILITY..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL
INFORMATION..........................................................................26
CLINICAL TRIALS
..........................................................................................................27
DETAILED PHARMACOLOGY
.....................................................................................27